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Abstract
Autism spectrum disorder (ASD) is characterized as a developmental disability caused by abnormalities in brain function. Studies
link ASD with various physiological abnormalities, such as cerebral hypoperfusion, oxidative stress, inflammation, and mitochondrial dysfunction. Studies show that diminished blood flow to the brain demonstrates a connection between several core autistic
behaviors, and the hypoperfusion generally worsen with age, growing more prevalent in older children. Although hyperbaric oxygen
therapy (“HBOT”) is not yet approved by the United States Food and Drug Administration ) (“FDA”), several studies performed
internationally have proven its efficacy in treating people with autism. Even so, the FDA does approve of its use for other medical
conditions such as decompression sickness (the bends) experienced by divers, treatment of air or gas embolism, carbon monoxide
poisoning , and thermal burns. Hyperbaric oxygen therapy chambers expose the patient to 100% oxygen (unlike the 21% oxygen
found in the air we breathe) by increasing the air pressure in the chamber up to three times higher than normal air pressure of
1 atm. This allows the lungs to take in more than the expected amount of oxygen and thus be distributed throughout the body
to the cells that are deprived of oxygen. This paper examines the effectiveness of HBOT in children with ASD, by reviewing the
available research.
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by “persistent deficits in social
communication and social interaction across multiple
contexts and restricted repetitive patterns of behavior,
interests, or activities,” (APA, 2013). ASD includes autistic
disorder, pervasive developmental disorder, and Asperger
syndrome. Approximately 1 out of 110 people in the
United States are currently affected by ASD (Rice, 2006).
The cause of ASD is unclear. Although several genetic
syndromes, such as Fragile X and Rett syndromes, have
been linked with ASD, the majority of ASD cases are not
due to a simple single gene or chromosomal disorder;
studies have estimated that genetic syndromes only account for 6-15% of ASD cases (Schaefer & Mendelsohn,
2008). Recently, research and clinical studies in ASD have
linked physiological abnormalities, such as cerebral hypoperfusion, inflammation, oxidative stress, mitochondrial
dysfunction and immune dysregulation (Rossignol & Frye,
2012). With this perspective, ASD may consist of physiological irregularities rather than merely a CNS disorder
(Herbert, 2005). Treating ASD is not a simple matter;
there are a limited number of treatments. The behavioral
aspects of ASD are manageable with the help of behavioral therapies. Applied behavioral analysis (ABA), specifically,
has been proven to lead to advances in certain children
with ASD. In two years, ABA brought about remarkable
improvements in the IQ and behavioral issues of several
children with ASD (Lovaas, 1987). After four years, ABA
researchers at the Wisconsin Early Autism project found
analogous results of improved IQ and behavior (Sallows
& Graupner, 2005). Conversely, researchers in Norway
found that eclectic therapy (a form of psychotherapy)
was successful in the treatment of children with ASD
who were observed for only one year.The results proved
to supersede the effective outcomes of ABA (Eikeseth,
et al., 2002). When it comes to cognitive and behavioral

transformations in children with ASD, behavioral therapies are not an ideal approach, as they are quite time demanding. Additional treatments for ASD that aim to treat
physiological irregularities have been conveyed, yet, a
majority of these forms of treatments have not been critically assessed. However, many studies were performed
to test the effects of HBOT to treat the physiological abnormalities possessed by people with ASD, many of which
have shown promising results.
Methods
The research incorporated in this paper was retrieved
from original research papers and scholarly articles obtained through Touro College’s library of databases, such
as ProQuest and EBSCO. Google scholar, and PubMed
were also used to acquire data. The articles chosen were
critically assessed, compared, and analyzed to evaluate if
hyperbaric oxygen therapy is effective for treating autism
History of Hyperbaric Chambers
Hyperbaric air or “air under pressure” is a medical treatment that dates back over 150 years. In 1662, a British
physician created a sealed chamber in which the air was
compressed and decompressed using valves and oxygen.
This was extraordinary;it preceded the discovery of
oxygen and was utilized as a treatment for respiratory
diseases (Clarke, 2008). The idea of employing pressurized environments developed further in 1879, when the
French surgeon, Fontaine, built a pressurized mobile operating room. He observed that inhaled nitrous oxide
had greater efficacy when used under pressure. Patients
treated in an increased pressure environment were
not as cyanotic as those treated in standard conditions.
Additionally, his patients experienced improved oxygenation (Fontaine, 1879). In the early 1900’s, Dr. Orville
Cunningham, a professor of anesthesia, found a greater
improvement in heart disease victims when they resided
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closer to sea level than when they were living at higher
altitudes. Later, hyperbaric chambers were utilized by the
military, in the 1940’s, to treat deep-sea divers who experienced decompression sickness. In the 1950’s, physicians
first used HBOT during lung and heart surgery, which
steered to its use for carbon monoxide poisoning in the
1960’s. Since then, over 10,000 clinical trials and case
studies have been achieved for several other health-related purposes, with the great majority reporting successful
outcomes (Ohnishi, et al. 2000).
Hyperbaric oxygen therapy (HBOT)
Hyperbaric oxygen therapy (HBOT) is the medical use
of oxygen in a pressurized environment, and involves
breathing 100% oxygen while inside a hyperbaric chamber that exhibits pressures greater than sea level (1 atmosphere). The increased pressure permits oxygen to
dissolve and saturate the blood plasma (autonomous of
hemoglobin), which yields an extensive array of valuable
physiological and cellular outcomes. This noninvasive
therapy is the most reliable way to provide ample oxygen
to all organs of the body. The standard treatment lasts
for 60-90 minutes, during which the patient lies down
and breathes regularly (Feldmeier, 2003). The use of hyperbaric oxygen treatment (HBOT) was implemented
as a treatment method for numerous clinical disorders.
It has been proven in several clinical studies to enhance
the body’s inherent ability to regenerate and repair. It is
used as a therapy to facilitate the healing process in both
chronic and acute disorders. Decompression sickness,
stroke victims, arterial gas embolism, healing of wounds,
severe carbon monoxide poisoning and smoke inhalation
are only some of the common uses of HBOT. However,
in 2005, researchers began to consider using HBOT to
improve behavioral and physiological abnormalities found
in individuals with ASD (Leach, et al. 1998). This paper will
evaluate the current data on treating ASD with HBOT.
First, the effects of HBOT on physiological irregularities
in children with ASD will be evaluated. Then, the effects
on autistic behaviors will be examined. Finally, the apparent contrary effects of HBOT in ASD and restrictions of
studies will be assessed.
Cerebral Hypoperfusion in ASD and the Effects
of HBOT
Cerebral hypoperfusion is characterized as insufficient
blood flow in the brain and is one of the common physiological abnormalities possessed by individuals with ASD.
Positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) were used in
studies to discern hypoperfusion exhibited in the brains of
66

people with ASD versus normal healthy brains (Bjørklund,
et al. 2018). Both PET and SPECT scans are types of nuclear imaging tests that utilize radioactive tracers to create three-dimensional images. However, they differ in the
radiotracers used. Studies have proven these scans to be
a reliable measure of cerebral blood flow in observing
what areas of the brain are receiving more blood flow.
(Amen, et al. 2011; NIH CC, 2002). Common autistic
behaviors such as need for consistency (Ohnishi, et al.
2000), habitual behaviors (Starkstein, et al. 2000), disability
in processing emotions and facial expressions (Critchley,
et al. 2000), and delayed language development (Wilcox,
et al. 2002), are linked to hypoperfusion. Moreover, hypoperfusion is related with increasing age in children with
ASD (Wilcox, et al. 2002). It is possible that HBOT could
improve cerebral hypoperfusion in ASD. Numerous studies were completed that evaluated the effects of HBOT
to treat various neurological disorders, such as chronic
brain injury and traumatic brain injury. The results of the
SPECT scans were evaluated before and after the delivery of HBOT at low pressures (1.3 to 1.5 atm). These
studies showed significant results (Harch, et al. 2012),
(Golden, et al. 2002). Histograms correlated to the pre
and post SPECT scans were analyzed with a widely used
medical images software called Osirix DICOM. Results
from both scans showed significant pattern differences
beneath the cerebral cortex in the central area of white
matter, known as the centrum ovale. The pre-HBOT images displayed a larger array of counts in the histograms
than in the post-HBOT. The narrower range of counts in
the post-HBOT corresponded to the increase of perfusion to the lacking areas. The effectiveness was studied
through many areas in addition to SPECT: physical exam,
symptoms, and psychological measurement (Harch, et al.
2012). Moreover, numerous case studies have reported
enhancements in cerebral perfusion after HBOT treatment. One study involved a child with ASD who received
one hour of HBOT at 1.3 atm and 24% oxygen per day for
ten days (Heuser, et al. 2002). The SPECT scans revealed
increased perfusion. However, the effects of ten treatments only lasts several months. For longer lasting effects
(6-18 months) more treatments are necessary (20-60
treatments). Behavioral improvements were detected in
this child including cognitive and memory functions. The
child became sympathetic, started to point and articulate,
and interact with others. Another child with ASD, who
received 40 treatments of HBOT at 1.3 atm and 24%
oxygen, also presented behavioral improvements, such
as, improvements in speech and communication and fine
motor skills (Rossignol, 2008).
Another study involved 108 children with ASD who
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experienced decreased perfusion in their temporal lobes
as measured by SPECT scans (Kinaci, et al. 1970). They
received HBOT at 1.5 atm with 100% oxygen for an hour
a day for 50 days. After their treatments, SPECT scans
revealed that 82.40% showed improvements in their
temporal lobes, 85.26% in their frontal lobes, and 75.75%
in other areas. Furthermore, clinicians did an Autism
Treatment Evaluation Checklist (ATEC) on 54 of the individuals and significant improvements were noted: 85.5%
in Sociability, 79% in Speech/Language/Communication,
75.2% in Health/Physical/Behavior, and 87% in Sensory/
Cognitive Awareness. This study revealed major improvements in the physical, behavioral and cerebral perfusion of
children with ASD after HBOT (Kinaci, et al. 1970). This
study is reliable due to the large sample size, unbiased
SPECT imaging, and therapist assessments.
Oxidative Stress in ASD and the Effects of HBOT
Oxidative stress is defined as an imbalance between the
production of reactive oxygen species (free radicals) and
antioxidant defenses. Some children with ASD experience
oxidative stress. Some researchers believe that HBOT indirectly causes an increase in oxidative stress due to the
amplified production of reactive oxygen species (“ROS”)
from the elevated oxygen levels (Alleva, et al. 2005).
Therefore, they are reluctant to use HBOT on children
with ASD, since some of them already have elevated oxidative stress levels (Rossignol, et al. 2007). A contributing
factor to their increased oxidative stress levels might be
due to the excessive amounts of oxygen supply to their
cell’s mitochondria, which can escalate the production of
ROS. In contrast, HBOT has proven to upregulate antioxidant enzyme production that can aid with detoxification
issues found in children with ASD such as glutathione
peroxidase, superoxide dismutase (Gulec, et al. 2004),
and catalase (Nie, et al. 2006). The antioxidant enzyme
level increase can protect against harm initiated by ROS
(Rossignol, 2007). Additionally, minor elevations in ROS
created by HBOT can be advantageous, as they increase
mitochondrial biogenesis (Gutsaeva, et al. 2006).
Two studies have observed the influences of HBOT
on oxidative stress in children with autism (Audhya,
2007; Rossignol, et al. 2007). The first study included administering HBOT at 1.3 atm daily to 48 children with
autism. Catalase, glutathione peroxidase and superoxide
dismutase (SOD) levels were screened before beginning
HBOT and again after day 1 and day 32 of HBOT (Audhya,
2007). Results demonstrated a 1.9-fold increase of the
original catalase levels after the first day and a 90% improvement after 32 days. Glutathione peroxidase showed
a 1.4-fold increase after 1 day and a 1.2-fold increase after

32 days from the initial HBOT. Finally, a 4.5-fold increase
of SOD was observed after 1 day and a 4.7-fold increase
after 32 days of starting HBOT. The results of HBOT on
antioxidant enzymes can be considered conditioning.
The second study involved 18 autistic children from
ages 3-16. This open label, prospective study included administering 40 treatments of HBOT, with 24% oxygen, at
1.3 atm, to 12 children, and 100% oxygen at 1.5 atm to 6
children. Blood markers were taken before and after 40
treatments (Rossignol, et al. 2007). Researchers noticed
dramatic improvements in speech, socialization, GI function, and strength. The effects persisted months after the
study was completed. Furthermore, insignificant changes were seen in plasma-oxidized glutathione levels. This
proves that oxidative stress markers did not worsen because oxidized glutathione is transported from within the
cells when intracellular levels surpass the redox capacity
(Dickinson and Forman, 2002). However, the intracellular oxidative stress levels in the children with ASD did
not diminish with the lower HBOT pressures (Rossignol,
et al. 2007). The open-label nature of this study and the
two diverse treatment groups (one group who received
24% oxygen at 1.3 atm versus the other group who received 100% oxygen at 1.5 arm), as well as the absence
of a control group, are some of the limitations of this
study. Nonetheless, the prospective nature of this study
strengthens it.
Inflammation in ASD and the Effects of HBOT
Some individuals with ASD experience inflammation, such
as neuroinflammation, gastrointestinal inflammation and
immune dysregulation as supported by recent studies.
Numerous studies have conveyed atypical inflammatory
indicators in children with ASD. For instance, increases
in Tumor Necrosis Factor-alpha (TNF-alpha) (Chez, et al.
2007), and neopterin (cellular immune system activation
marker) (Messahel, et al. 1998), were related in studies
of children with ASD. Additionally, studies showed that
children with ASD, who reported having gastrointestinal
inflammation, have analogous symptoms to one suffering
from inflammatory bowel disease (IBD) (Ashwood, et
al. 2003). Anti-inflammatory results were reported after
treatment with HBOT. A decrease in pro-inflammatory
cytokines (including TNF-alpha, IL-1 and IL-6) (Weisz, et
al. 1997), and an increase in counter-inflammatory IL-10
levels were reported after HBOT (Buras, et al. 2006).
Moreover, improvements in IBD were reported in a
systematic review that used HBOT (Rossignol 2012).
A study reported a decrease in production of interferon-gamma by lymphocytes with HBOT at 2.0 atm/10.5%
oxygen, but an increase in interferon-gamma with 100%
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oxygen administered at 1.0 atm (Granowitz, et al. 2002).
Therefore, it is concluded that the result of HBOT on
reducing inflammation is facilitated through the pressure-related component and not particularly on the delivery of oxygen.
Unfortunately, a series of recurring events can cause
amplified inflammation which can lead to escalated cerebral hypoperfusion. This may cause hypoxia, which leads
to production of HIF-1a (hypoxia-inducible factor-1alpha)
which induces inflammation (Nathan, 2003). HIF-1a is
fundamental in the innate immune system, as it triggers
inflammation by myeloid cells (Cramer, et al. 2003).
The effects of HBOT on biomarkers of inflammation
in children with ASD were inspected in two prospective
studies. The first study included 12 children who were
given 40 treatments of HBOT at 1.3 atm/24% oxygen
and 6 children who were given HBOT at 1.5 atm/100%
oxygen. Biomarkers were measured before and after the
treatments by testing the participants’ blood specimens
taken before and after the treatments (Rossignol, et al.
2007). Improvements were seen in C-reactive proteins
(non-specific inflammation markers), as their levels decreased in the total study population (p=0.021).The most
significant decrease was seen in children with the highest
levels of C-reactive proteins prior to the study. These
children also showed behavioral improvements. SRS
(Social Responsiveness Scale), ABC-C (Aberrant Behavior
Checklist – Community), and ATEC (Autism Treatment
Evaluation Checklist) were filled out by the parents and
were used to calculate the scores for each child before
and after their treatments.
The second study measured plasma cytokine levels, including some related to inflammation prior to and after
HBOT.Ten children with ASD participated in this 20 week
study with 80 sessions of HBOT given to them at 1.5
atm/100% oxygen (Bent, et al. 2012). Although the study
reported behavioral improvements, negligible modifications were observed in cytokines. Yet, the authors mentioned that none of the children actually had irregular
cytokine levels prior to the study, so notable variations
could not be seen.
In another study, a child with ASD who suffered from
eczema and bowel inflammation, with a distended abdomen, displayed significant improvements after 40 treatments of HBOT at 1.5 atm and 100% oxygen over the
course of a month (Rossignol 2008).
Mitochondrial Dysfunction in ASD and the
Effects of HBOT
Mitochondrial dysfunction is observed in some people
with ASD (Rossignol & Frye, 2011; Frye & Rossignol, 2011).
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HBOT is considered a possible treatment for mitochondrial dysfunction, although treatments for this condition
are minimal (Rossignol & Frye, 2011). The outcomes of
HBOT on mitochondrial dysfunction were measured in
various studies.
In a controlled study HBOT at 1.5 atm and 100%
oxygen was administered to 69 patients who obtained
severe traumatic brain injury (TBI), within 24 hours of injury. Significant increases in brain oxygen concentrations
were seen, as well as increases in cerebral blood flow
and reduced CSF lactate levels (elevated CSF lactate is
an indicator of mitochondrial dysfunction). Results also
showed improvements in mitochondrial function and
brain metabolism after contrasting both room air treatment of 21% oxygen and 100% oxygen given at normal
pressure (1 atm) (Rockswold, et al. 2010).
HBOT can make more electron transport chains in
mitochondria. In 2008, a study was conducted on healthy
rat tissue (Kurt, et al. 2008). HBOT was done on the rat
and the tissues were looked at before and after the treatment. Results showed that the mitochondria were working more efficiently. Mitochondria work more efficiently
through physical exercise. During exercise, the cells are
stressed and mitochondria are making more electron
transport chains. Similarly, with HBOT, the cells are slightly stressed and they make more electron transport chains
thereby working more efficiently and experiencing less
oxidative stress.
Furthermore, a study was conducted in 2006, which
showed it is possible to increase the number of mitochondria in the brain cells of rats. This phenomenon is
called mitochondrial biogenesis (Gutsaeva et al. 2006).
This was not demonstrated in humans, because it would
require risky brain biopsies to be performed on patients.
This can be one possible mechanism as to why HBOT is
working. Although these results seem promising, no clinical studies were performed to test the effects of HBOT
on mitochondrial dysfunction in children with ASD.
Behavioral Measurements in ASD and the Effects
of HBOT
Most of the studies performed using HBOT for children with ASD have inquired behavioral rather than
physiological factors. In a current systematic review,
two double-blind, arbitrary, controlled trials were reviewed regarding the use of HBOT in children with ASD
(Ghanizadeh, 2012).The first study examined the outcome
of giving 33 children with ASD, 40 treatments of HBOT
with 24% oxygen at 1.3 atm, which included 2 treatments
each day for 5 days a week, over the course of 4 weeks.
This study was performed in comparison to 29 control

Is Hyperbaric Oxygen Therapy Effective For Treating Autism?

children with ASD who were given room air that was
slightly pressurized (1.03 atm/21% oxygen) (Rossignol, et
al. 2009). Noteworthy improvements were detected in
the treated children on the ATEC scales (questionnaire
that measures changes in severity of ASD in response to
treatment) by the caregiver, as well as on the CGI scales
(Clinical Global Impression rating scales: measures the
severity of symptoms, treatment response and the effectiveness of treatments) by the clinicians and parents. The
results showed improvements in language, eye contact,
cognitive attentiveness and overall functioning. Strengths
of this study comprise of the involvement of 6 medical
centers (which limited possible biases correlated to a
specific site study), assessments by blinded parents and
clinicians and the use of a control group.
The second study examined the outcome of giving 18
children with ASD, 80 treatments of HBOT with 24% oxygen at 1.3 atm, within a 15 week duration. These results
were compared to 16 children who were treated with a
placebo, involving air flowing through a chamber at normal
pressure. Subsequently, ABA therapy was given to both
groups, yet insignificant changes were observed using various behavioral scales (Granpeesheh, et al. 2010). These
undesirable results can be attributed to the fact that rigorous ABA therapy was given during the administration
of HBOT which did not seem successful (Ghanizadeh,
2012). On the other hand, this study is reliable because of
the blinded evaluators as well as the control group. The
contrasting results can be ascribed to the discrepancies
among the two controlled trials (Ghanizadeh, 2012). For
example, the age and quantity differences of the participants, as well as the magnitude of treatments. One study
delivered 10 hours of HBOT per week (Rossignol, et al.
2009). While the other study provided 5 hours per week
(Granpeesheh, et al. 2010). There were also probable distinctions in ASD severity.
Antagonistic Properties of HBOT in ASD
Among the many studies performed, minimal unfavorable
outcomes were reported of HBOT usage for people with
autism. One study stated that “HBOT was safely administered to autistic children and all participants were able
to finish 40 HBOT sessions without any major adverse
events” (Rossignol, et al. 2007). A different study informed
minor antagonistic effects, including 4 kids with earaches,
2 kids with otitis media and other individuals who were
autonomously affected with insomnia, seizures, lethargy,
amplified vocal sensitivity and hyperactivity (Bent, et al.
2012). In a controlled study, one of the participants experienced frequent urination and a skin rash which the
doctor attributed to yeast as the causing factor. Other

participants withdrew from the study, specifically one
child who experienced regressing symptoms of asthma after several HBOT treatments. The physicians did
not think the two were related, but removed the child
as a safeguard. Another child withdrew from the study
before completing it due to anxiety. One participant in
the control group experienced diarrhea and abdominal
swelling, yet still completed the experiment. In addition,
another control group participant experienced worsening of pre-existing eczema. Seizures or barotrauma,
however, were not detected in neither the treatment nor
control groups (Rossignol, et al. 2007). In a study performed on the effects of HBOT in Thai autistic children,
it was reported in the data analysis that “there was no
serious adverse effect in any case and tinnitus was a mild
side effect in one case and it went away in one week”
(Chungpaibulpatana, et al. 2008).
According to the FDA, “patients receiving HBOT are
at risk of suffering an injury that can be mild (such as
sinus pain, ear pressure, painful joints) or serious (such
as paralysis, or air embolism). Since hyperbaric chambers
are oxygen rich environments, there is also a risk of fire”
(FDA commissioner, 2013) .
Restrictions of the Studies Performed
Most of the studies performed contain restraints that
contribute to the erratic results among them, including
the retrospective approaches, the absence of control
participants and the minimal amount of participants.
Moreover, the open trials increase bias, as both the participants and the researchers are aware which treatment
is being given. However, two of the controlled studies did
not contain these restraints. Furthermore, other studies
utilized observational methods which are not efficient
when analyzing modifications in memory and attentiveness (Jepson, et al. 2011). Unfortunately, the long-term
effects of HBOT are unknown because once the study
was complete researchers did not follow up on the
long-lasting effects. Additionally, a majority of the studies
focused on behavioral modifications rather than physiological modifications. Earlier studies proved that ABA
therapy in individuals with autism is only effective when
done over a substantial period of time. For example, ABA
therapy studies displayed significant behavioral changes
over a one to four year duration (Lovaas, 1987; Sallows &
Graupner, 2005).
It is common for the physiological modifications seen
in autistic children treated with HBOT to be observed
before intellectual and developmental enhancements due
to the intricacies of brain maturation. Studies have found
significant physiological improvements after a short time
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in participants who were treated with HBOT, specifically
modifications with cerebral hypoperfusion. While most
of the studies noted behavioral enhancements in several children with autism, the studies only persisted for a
few months. This short duration of time is not enough
to determine the influence HBOT has on development.
Further studies are necessary to investigate the long lasting results of HBOT in people with autism.
Many studies noted behavioral and physiological advances when treating autistic children using HBOT. Yet,
noteworthy developments were not found when researchers from a common group performed two studies
(Granpeesheh, et al. 2010; Jepson, et al. 2011), and insignificant results were noticed in a different minor study
(Lerman, et al. 2009). The inconsistent outcomes among
the studies may be attributed to the autistic children’s
opposing responses to HBOT (Jepson, et al. 2011). To
illustrate, children who possess certain physiological abnormalities such as mitochondrial dysfunction, cerebral
hypoperfusion and inflammation might be more prone to
display improvements. Nevertheless, most of the studies
performed to test behavioral aspects did not analyze the
chemical aspects such as levels of oxidative stress or inflammatory markers. However, one behavioral study did
analyze alterations in the levels of cytokine, but insignificant modifications in cytokines were seen because all the
participants already had regular cytokine levels prior to
their HBOT treatment (Bent, et al. 2011).
Further investigation is required including participants
with ASD who possess specific physiological abnormalities and which analyze variations in these physiological
issues such as cerebral hypoperfusion and inflammation.
Noteworthy improvements were related in studies which
administered HBOT sessions more frequently. This also
seemed true in studies that used HBOT to treat patients
with traumatic brain injuries, (Harch, et al. 2012). More
studies, however, are needed to analyze several HBOT
factors, such as the ideal oxygen and pressure limits required to treat patients with ASD.
HBOT in Thailand
In 2008, the first study in Thailand was performed to determine the effects of HBOT to treat autistic children and
whether it is safe or not (Chungpaibulpatana, et al. 2008).
The study included 7 Thai autistic children who received
10 sessions of HBOT once a week at 1.3 atm. Before and
after the treatments, five areas were evaluated: “1. Social
development 2. Fine motor and Eye-hand coordination 3.
Language development 4. Gross motor development 5.
Self - help skills” (Chungpaibulpatana, et al. 2008). Results
showed advances within these five domains with 75% of
70

children who displayed progress while 25% showed no
reaction to the treatment.
FDA Approval
Although HBOT is currently being used as a treatment
method to treat various disorders in Thailand such as
autism, it has not been clinically verified or cleared by
the FDA to cure or be successful in the treatment of autism, cancer, or diabetes (FDA, 2013). However, the FDA
did approve the use of HBOT for several other conditions. These include “treatment of air or gas embolism
(dangerous ‘bubbles’ in the bloodstream that obstruct
circulation), carbon monoxide poisoning, decompression
sickness (‘the bends’), and thermal burns (caused by heat
or fire),” (FDA, 2013).
Disadvantages
Dr. Paul Claus, medical director of Mayo Clinic’s
Hyperbaric and Altitude Medicine Program, relates risk
factors of HBOT. The increased oxygen of the chamber
supports combustion which poses a risk for fires in the
facility. Therefore, necessary precautions are taken. The
patients are required to remove their street clothes since
polyester is fuel for fire. The patients are provided with
cotton blend clothing instead.Additionally, the treatments
are quite expensive; they are approximately $1,500 an
hour in most hospital settings (Claus, 2017). However,
if more studies are done documenting improvements of
HBOT, then hopefully the cost will be covered by the
healthcare system or insurance companies to further
benefit those with autism. .
Conclusion
“There is no one-answer for many questions but there
are many answers for one question. Multiple factors are
the possible causes of autism.The curative factors may be
from multidisciplinary approaches,” (Chungpaibulpatana,
et al. 2008). Numerous studies have demonstrated that
HBOT is an effective treatment for children with autism.
The pressures utilized during treatment with HBOT (1.5
atm/100% oxygen maximum) are proven to improve the
common physiological abnormalities in individuals with
ASD; such as, cerebral hypoperfusion, oxidative stress, inflammation and mitochondrial dysfunction. Furthermore,
studies that targeted the behavioral measurements in
ASD also showed positive results even though most of
those studies did not use control groups.The two studies
that did utilize control groups however related opposing
outcomes. However, multiple crucial variations between
the trials were noted. Taken together, the studies imply
that the use of HBOT in children with autism correlates
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with marginal antagonistic effects and is handled well. In
conclusion, HBOT is a harmless and possibly beneficial
treatment for kids with autism. However, additional studies are necessary before it can become an internationally
accepted treatment method. Future studies should be
more specific and directed towards the specific physiological abnormalities within the various ASD subdivisions
and should use control groups as well to promote efficiency and determine which people can gain from HBOT
treatment. Furthermore, why don’t the hospitals in
Thailand publish anything regarding their routine HBOT
usage? They value intellectual property not academic
publications. If it were not more clinically effective than
the use of HBOT would not be used regularly and its
ineffectiveness would spread like wildfire. Based on the
studies performed, overall, the use of hyperbaric oxygen
therapy appears to be a promising treatment for children
with ASD.
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